Twice Weekly versus Thrice Weekly Hemodialysis-A Pilot Cross-Over Equivalence Trial

Background The 2015 Update of the Kidney Disease Outcomes Quality Initiative (KDOQI) Guideline for Hemodialysis Adequacy increased the contribution of residual kidney function in calculating standard Kt/Vurea (stdKt/Vurea). However, no study has assessed the effect of prescribing twice weekly hemodialysis according to this guideline on patients' quality of life or uremic solute levels. Methods Twenty six hemodialysis patients with average residual urea clearance (Kru) 4.7 +/- 1.8 ml/min and hemodialysis vintage of 12 +/- 15 months (range 2 months to 4.9 years) underwent a cross-over trial comparing four weeks of twice weekly hemodialysis and four weeks of thrice weekly hemodialysis. Twice weekly hemodialysis was prescribed to achieve stdKt/Vurea 2.2 incorporating Kru using the 2015 KDOQI Guideline. Thrice weekly hemodialysis was prescribed to achieve spKt/Vurea 1.3 regardless of Kru. Quality of life and plasma levels of secreted uremic solutes and beta 2 microglobulin were assessed at the end of each period. Results Equivalence testing between twice and thrice weekly hemodialysis based on the Kidney Disease Quality of Life instrument (primary analysis) was inconclusive. Symptoms as assessed by the secondary outcomes Dialysis Symptom Index and Post-Dialysis Recovery Time were not worse with twice weekly hemodialysis. StdKt/Vurea was adequate during twice weekly hemodialysis (2.7 +/- 0.5), and ultrafiltration rate and plasma potassium were controlled with minimally longer treatment times (twice weekly: 195 +/- 20 versus thrice weekly: 191 +/- 17 minutes). Plasma levels of the secreted solutes and beta 2 microglobulin were not higher with twice weekly than thrice weekly hemodialysis. Conclusions Twice weekly hemodialysis can be prescribed using the higher contribution assigned to Kru by the 2015 KDOQI Guideline. With twice weekly hemodialysis, quality of life was unchanged, and the continuous function of the residual kidneys controlled fluid gain and plasma levels of potassium and uremic solutes without substantially longer treatment times.Clinical Trial registration number:NCT03874117.